Tepezza is the first drug Horizon has shepherded through the FDA's Biologics License Application process, "a key step in our evolution to an innovation-focused biopharma company," CEO Tim Walbert said in a statement. The FDA based its approval on phase 3 data showing 82.9% of Tepezza patients achieved a 2-mm or greater reduction in proptosis––or eye bulging––after 24 weeks compared with 9.5% of placebo patients. The drug also showed it could reduce clinical symptoms, ease double vision and improve patients' quality of life.